Literature DB >> 3196882

Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.

M Freund1, P von Wussow, J Knüver-Hopf, H Mohr, U Pohl, G Exeriede, H Link, H J Wilke, H Poliwoda.   

Abstract

A patient with Philadelphia-chromosome positive chronic myelogenous leukemia developed interferon antibodies on treatment with recombinant interferon alpha-2b. Clinically this event corresponded with progressive disease. No cross-reactivity of antibodies with human leukocyte interferon was found by Western blot. Treatment was switched to human leukocyte interferon with an obvious clinical effect: WBC was reduced and platelet count stabilized, but the effect was transient and no hematologic remission was achieved. Human leukocyte interferon may be an alternative in CML-patients with neutralizing antibodies to recombinant interferon alpha.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3196882     DOI： 10.1007/bf00320360

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  22 in total

1.  Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection.

Authors:  L M Itri; M Campion; R A Dennin; A V Palleroni; J U Gutterman; J E Groopman; P W Trown
Journal:  Cancer       Date:  1987-02-01       Impact factor: 6.860

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  Interferon bioassay methods and the development of standard procedures: a critique and analysis of current observations.

Authors:  S E Grossberg; P Jameson; J J Sedmak
Journal:  In Vitro Monogr       Date:  1974

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b.

Authors:  P von Wussow; F Hartmann; M Freund; H Poliwoda; H Deicher
Journal:  Lancet       Date:  1988-04-16       Impact factor: 79.321

6.  Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

Authors:  I Cunningham; T Gee; M Dowling; R Chaganti; R Bailey; S Hopfan; L Bowden; A Turnbull; W Knapper; B Clarkson
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

7.  Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells.

Authors:  H E Broxmeyer; L Lu; E Platzer; C Feit; L Juliano; B Y Rubin
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

8.  Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K B McCredie; M J Keating; J Trujillo; J Gutterman
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

9.  A radioimmunologic technique to screen for antibodies to alpha-2 interferon.

Authors:  W P Protzman; S L Jacobs; M Minnicozzi; E M Oden; D K Kelsey
Journal:  J Immunol Methods       Date:  1984-12-31       Impact factor: 2.303

10.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K McCredie; J M Trujillo; M J Keating; J U Gutterman
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245
View more
  2 in total

1.  Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia.

Authors:  Carolina Scagnolari; Milvia Casato; Francesca Bellomi; Francesca De Pisa; Ombretta Turriziani; Rossella Coviello; Maria Rosaria Pirro; Ferdinando Dianzani; Guido Antonelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

2.  Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.

Authors:  J B Bell; R Barfoot; T Iveson; R L Powles; B C Millar
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.